Novo Nordisk’s Wegovy may just have two years to take over China’s market for weight loss drugs
Novo Nordisk's China patent on Wegovy's active ingredient expires in 2026, much earlier than its patents in the U.S., Japan and Europe.
Novo Nordisk's China patent on Wegovy's active ingredient expires in 2026, much earlier than its patents in the U.S., Japan and Europe. Read More
